Targeting Gut Microbiota in Cancer Cachexia: Towards New Treatment Options.
Concetta PanebiancoAnnacandida VillaniAdele PotenzaEnrica FavaroConcetta FinocchiaroFrancesco PerriValerio PazienzaPublished in: International journal of molecular sciences (2023)
Cancer cachexia is a complex multifactorial syndrome whose hallmarks are weight loss due to the wasting of muscle tissue with or without the loss of adipose tissue, anorexia, systemic inflammation, and multi-organ metabolic alterations, which negatively impact patients' response to anticancer treatments, quality of life, and overall survival. Despite its clinical relevance, cancer cachexia often remains an underestimated complication due to the lack of rigorous diagnostic and therapeutic pathways. A number of studies have shown alterations in gut microbiota diversity and composition in association with cancer cachexia markers and symptoms, thus supporting a central role for dysbiosis in the pathogenesis of this syndrome. Different tools of microbiota manipulation, including probiotics, prebiotics, synbiotics, and fecal microbiota transplantation, have been investigated, demonstrating encouraging improvements in cachexia outcomes. Albeit pioneering, these studies pave the way for future research with the aim of exploring the role of gut microbiota in cancer cachexia more deeply and setting up effective microbiota-targeting interventions to be translated into clinical practice.
Keyphrases
- papillary thyroid
- squamous cell
- adipose tissue
- weight loss
- clinical practice
- end stage renal disease
- stem cells
- lymph node metastasis
- bariatric surgery
- squamous cell carcinoma
- ejection fraction
- chronic kidney disease
- skeletal muscle
- mesenchymal stem cells
- childhood cancer
- insulin resistance
- cancer therapy
- drug delivery
- metabolic syndrome
- high fat diet
- cell therapy
- case report
- case control